+Search query
-Structure paper
Title | Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. |
---|---|
Journal, issue, pages | Nat Biotechnol, Vol. 40, Issue 8, Page 1270-1275, Year 2022 |
Publish date | Mar 3, 2022 |
Authors | Andrea R Shiakolas / Kevin J Kramer / Nicole V Johnson / Steven C Wall / Naveenchandra Suryadevara / Daniel Wrapp / Sivakumar Periasamy / Kelsey A Pilewski / Nagarajan Raju / Rachel Nargi / Rachel E Sutton / Lauren M Walker / Ian Setliff / James E Crowe / Alexander Bukreyev / Robert H Carnahan / Jason S McLellan / Ivelin S Georgiev / |
PubMed Abstract | Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development ...Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target-ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target-ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies. |
External links | Nat Biotechnol / PubMed:35241839 / PubMed Central |
Methods | EM (single particle) |
Resolution | 8.64 Å |
Structure data | EMDB-26064: |
Source |
|